Business Context and Reporting Period
This Form 8-K was filed by Aquinox Pharmaceuticals, Inc. on November 7, 2018. The filing serves to announce the company's financial results for the quarter ended September 30, 2018. The full details of these results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K document.
Material Changes
The filing does not explicitly list material changes versus the prior comparable period within the text provided. It directs readers to the attached press release for the announcement of financial results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in this report and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not incorporated by reference into any other filings under the Securities Act or the Exchange Act. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated November 7, 2018), as they are not listed in this summary document.
- Confirm the company's operational status and pipeline updates mentioned in the referenced press release.
- Note that the financial data in this filing is "furnished" and not "filed," meaning it carries different legal weight regarding incorporation by reference in future documents.